Literature DB >> 1130635

[The metabolism of pancuronium in man].

W Buzello.   

Abstract

The metabolic disposition of pancuronium was investigated in man under clinical condition. Pancuronium and its desacetylated derivatives were determined in body fluids using the previously described bromophenol blue method (3). The metabolites were isolated by thin layer chromatography. One minute after the intravenous injection of a mg of pancuronium the drug reaches a serum concentration of 2,2 plus or minus 0,2mug/ml. As an exponential function the concentration curve then falls to half of the initial value during the first 30 to 60 min. The end of the neuromuscular block conincides with a concentration of 0,1 to 0,3 mug/ml serum which is reached about 2 hours after the injection. After 3 to 4 hours no more pancuronium can be detected in the serum. The renal elimination of pancuronium can be folowed up for 12 hours. On average half of the injected dose is recovered in the urine. 80% of this proportion is unchanged pancuronium and 20% desacetylated metabolites. The monodesacetylated derivatives of pancuronium are still pharmacologically active. The biliary excretion 24 hours after the administration of pancuronium accounts for 5 to 10% of the injected dose...

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1130635

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  7 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Clinical pharmacokinetics of muscle relaxants.

Authors:  L B Wingard; D R Cook
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 3.  Org-NC45: a new steroidal non-depolarizing muscle relaxant.

Authors:  L H Booij; T B Vree; J E Crul
Journal:  Pharm Weekbl Sci       Date:  1982-02-19

Review 4.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Clinical pharmacokinetics of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

6.  The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

7.  Clinical pharmacokinetics of alcuronium chloride in man.

Authors:  J Walker; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.